Baseline characteristics

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer · Source last updated 2020-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      34

   units

   Participants

groups

1. description

   Phase I/II Cetuximab, Cisplatin and nab-paclitaxel concurrent with intensity-modulated radiotherapy.

   id

   BG000

   title

   Nab-Paclitaxel, Cisplatin, Cetuximab and Radiation Therapy

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            45

            upper Limit

            76

            value

            55.5

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. calculate Pct

   false

   classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            13

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            21

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            34

      title

      United States

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice